Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS

🇬🇷Greece

Country: 🇬🇷Greece

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

Phase 2

Recruiting

Conditions: Sepsis

Interventions: Drug: Placebo
Drug: Emapalumab-Izsg

First Posted Date: 2024-11-19

Last Posted Date: 2025-07-04

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 75

Registration Number: NCT06694701

Locations: 🇬🇷
1st Department of Internal Medicine, Thriasio Elefsis General Hospital, Elefsina, Attiki, Greece
🇬🇷
Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital, Kifissia, Attiki, Greece
🇬🇷
Intensive Care Unit, Herakleion University General Hospital, Heraklion, Crete, Greece

and more 21 locations

The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated with the Post-acute Phase of the Infection by Covid-19

Recruiting

Conditions: Pulmonary Complications
Cardiovascular Complications
Renal Complications
COVID-19

First Posted Date: 2024-09-23

Last Posted Date: 2025-03-17

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 345

Registration Number: NCT06608849

Locations: 🇬🇷
10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases, Athens, Greece
🇬🇷
Department of Internal Medicine, General Hospital of Argolida, Argos, Greece
🇬🇷
4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece

and more 4 locations

Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

Recruiting

Conditions: Pneumonia, Community-Acquired
COVID-19 Pneumonia
Cardiovascular Diseases

First Posted Date: 2024-09-19

Last Posted Date: 2025-06-22

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 650

Registration Number: NCT06601998

Locations: 🇬🇷
2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
🇬🇷
10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases, Athens, Greece
🇬🇷
1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece

and more 13 locations

Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

Phase 3

Recruiting

Conditions: Community-acquired Pneumonia

Interventions: Drug: Tablets
Drug: Clarithromycin 500mg

First Posted Date: 2024-03-05

Last Posted Date: 2024-10-23

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 330

Registration Number: NCT06294600

Locations: 🇬🇷
1st Department of Internal Medicine - General Hospital of Athens "Sismanogleio-Amalia Fleming", Athens, Greece
🇬🇷
1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Athens, Greece
🇬🇷
1st Department of Internal Medicine, EVANGELISMOS Athens General Hospital, Athens, Greece

and more 19 locations

NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification

Completed

Conditions: Pneumonia
Bacteremia
Biliary Tract Infection
Acute Pyelonephritis

First Posted Date: 2023-11-21

Last Posted Date: 2024-03-29

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 100

Registration Number: NCT06141395

Locations: 🇬🇷
4th Department of Internal Medicine,"Attikon" University Hospital, National and Kapodistrian University of Athens, Medical School, Chaïdári, Attiki, Greece
🇬🇷
1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens, Greece
🇬🇷
3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens SOTIRIA, Athens, Greece

and more 1 locations

Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

Phase 2

Recruiting

Conditions: Long COVID
Post-Acute COVID-19 Syndrome
Post-Acute COVID-19

Interventions: Drug: Placebo
Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret]

First Posted Date: 2023-07-03

Last Posted Date: 2024-12-03

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 182

Registration Number: NCT05926505

Locations: 🇬🇷
Out-patient long-COVID department X, Sotiria Athens Hospital of Chest Diseases, Athens, Greece
🇩🇪
Out-patient long-COVID department, Jena University Hospital, Jena, Germany
🇬🇷
Out-patient long-COVID department, Patras University General Hospital, Patra, Achaia, Greece

and more 21 locations

Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial)

Phase 3

Recruiting

Conditions: Sepsis

First Posted Date: 2023-06-18

Last Posted Date: 2024-05-31

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 190

Registration Number: NCT05909683

Locations: 🇬🇷
2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital, Athens, Chaidari, Greece
🇬🇷
4th Department of Internal Medicine, Attikon University Hospital, Athens, Chaidari, Greece
🇬🇷
1st Department of Internal Medicine, General Hospital of Elefsina "Thriasio", Athens, Elefsina, Greece

and more 9 locations

Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO

Completed

Conditions: Viral Infection
Multi-antibiotic Resistance
Bacterial Infections
Respiratory Tract Infections

First Posted Date: 2023-06-09

Last Posted Date: 2024-03-06

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 230

Registration Number: NCT05897801

Locations: 🇬🇷
Emergency Department of ATTIKON University General Hospital, Attiki, Chaidari, Greece
🇬🇷
Emergency Department of Tzaneion General Hospital, Attiki, Piraeus, Greece
🇬🇷
General Hospital of Elefsina 1st Department of Internal Medicine, Elefsína, Greece

Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia

Phase 2

Completed

Conditions: Hospital-acquired Pneumonia
Community-acquired Pneumonia

Interventions: Drug: Anakinra Prefilled Syringe
Drug: Placebo

First Posted Date: 2023-03-27

Last Posted Date: 2024-07-31

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 60

Registration Number: NCT05785442

Locations: 🇬🇷
4th Department of Internal Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece
🇬🇷
1st Department of Internal Medicine, General Hospital of Athens GENNIMATAS, Athens, Greece
🇬🇷
1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens, Greece

and more 2 locations

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

Phase 2

Completed

Conditions: Stool Microbiome
Organ Dysfunction Syndrome
Mortality
Clostridioides Difficile Infection Recurrence
Clostridioides Difficile Infection

Interventions: Drug: Normal saline 0.9% or 5% dextrose water
Drug: Bezlotoxumab

First Posted Date: 2022-03-31

Last Posted Date: 2023-12-15

Lead Sponsor: Hellenic Institute for the Study of Sepsis

Target Recruit Count: 44

Registration Number: NCT05304715

Locations: 🇬🇷
2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupoli, Greece
🇬🇷
1st Department of Internal Medicine, THRIASIO General Hospital of Eleusis, Athens, Greece
🇬🇷
2nd Department of Internal Medicine, Thriasio General Hospital, Athens, Greece

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy